ONO-4578, Opdivo and Chemo combo Met the Primary Endpoint in Ph 2 Trial in Patients with 1L HER2-neg recurrent Gastric Cancer October 15, 2025
AlphaMedix™ (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in Ph 2 study in patients with GEP-NETs October 15, 2025
Dosimetry Data from Ph 3 COMPETE Trial Supports Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with GEP-NETs October 15, 2025
Statistically Significant Final 2-Yr OS Data from Ph 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent Pulmonary Metastatic Osteosarcoma Announced October 15, 2025
Datroway demonstrated statistically significant OS & PFS improvement in 1L metastatic IO-ineligible TNBC patients in TROPION-Breast02 trial October 8, 2025
ASTRO 2025: Final Results from Pivotal Ph 3 METIS Trial of TTFields Therapy for Brain Mets from NSCLC presented October 8, 2025
Updated Ph 1 Results of JNJ-1900 (NBTXR3) + Anti-PD-1 in 1L/2L+ Anti-PD-1 Naïve or Resistant R/M-HNSCC Announced October 7, 2025
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent LG-IR NMIBC October 7, 2025
86% Reduction in Tumor Burden Announced in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen October 7, 2025
Encouraging Preliminary Results from the Pancreatic Cancer Cohort of Ph 1/2a CENDIFOX Trial of certepetide + chemo combo Announced September 30, 2025
Ph 3 EXCALIBER-RRMM Study of Iberdomide-SOC combo Demonstrated a Significant Improvement in MRD Negativity Rates in RRMM September 30, 2025
86% OS at 9 Months observed in 1L Pancreatic Cancer Patients Treated with Atebimetinib + mGnP September 30, 2025
Enhertu demonstrated statistically significant improvement in invasive DFS vs. T-DM1 in DESTINY-Breast05 Ph III trial in patients with high-risk early breast cancer following neoadjuvant therapy September 30, 2025
Pivotal Ziftomenib Data in R/R NPM1-Mutated AML Published in the Journal of Clinical Oncology September 30, 2025
ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable pancreatic cancer patients in Ph 2 AMPLIFY-7P Trial September 23, 2025
Extended Survival Achieved in Low PD-L1 Cohort in VERSATILE-002 Trial of PDS0101 (Versamune® HPV) + Keytruda in patients with HPV16-positive 1L R/M HNSCC September 23, 2025
100% MRD negativity seen in Ph 2 MajesTEC-5 study of TECVAYLI & DARZALEX FASPRO induction in transplant-eligible 1L multiple myeloma September 23, 2025
LP-184 Ph 1a Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors September 23, 2025
New Ph 2 Data for Stenoparib/2X-121 Showed Landmark Median OS Surpassing 25 Months September 23, 2025
IMNN-001 Ph 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift September 23, 2025
Positive Ph 3 Results Show Giredestrant Significantly Improved PFS in ER-Positive Advanced Breast Cancer September 23, 2025
Ph 1/2a Plixorafenib Data Demonstrated Prolonged Duration of Effect in BRAF Altered Thyroid Cancers September 23, 2025
